Six-Minute Walk Test Enhanced by Mobile Telemetric Cardiopulmonary Monitoring

Claudia Tueller a Lukas Kern b Andrea Azzola c Florent Baty b Sophie Condrau d Jan Wiegand e Michael Tamm d Martin Brutsche b

a Department of Pulmonary Medicine, University Hospital Bern, Bern, b Division of Pulmonary Medicine, Cantonal Hospital St. Gallen, St. Gallen, c Regional Hospital Lugano, Lugano, d Division of Pulmonary Medicine, University Hospital Basel, Basel, and e Division of Critical Care Medicine, University Hospital Bern, Bern, Switzerland

Abstract

Background: The 6-min walk test (6MWT) is frequently used to assess overall cardiopulmonary fitness and to predict outcome, but it yields little diagnostic information. Portable telemetric devices allow performing the 6MWT with real-time cardiopulmonary monitoring. Objectives: The study was designed to analyze feasibility, safety and clinical usefulness of a mobile cardiopulmonary monitoring (MOB)-enhanced 6MWT. Methods: From August 2003 to June 2007, 261 consecutive patients with chronic lung and/or heart disease as well as healthy controls underwent MOB-enhanced 6MWTS. A subgroup of 33 individuals had the test done with and without cardiopulmonary monitoring on independent days. Results: No test-related adverse events occurred throughout the study. Whether the 6MWT was done without or with cardiopulmonary monitoring (n = 33) did not significantly influence the walking distance (WD: 528 ± 183 vs. 525 ± 192 m; nonsignificant). Fifty-nine percent (155/261) of the patients fulfilled the maximal test criteria. Distinct disease-specific exercise response patterns as well as treatable co-pathologies were observed. The validity of response patterns was better in case of a maximal test. Conclusion: An MOB-enhanced 6MWT is feasible within daily routine and safe in patients with various diseases. It does not negatively affect WD. MOB is a valuable tool to identify factors limiting exercise in patients irrespective of their underlying disease.

Introduction

Walking tests have been used for many years to assess overall performance status of patients with different underlying diseases [1, 2]. The 6-min walk test (6MWT) has been extensively investigated and correlates well with impairment in activities of daily life [3]. It is currently used as an indicator when to put patients on a lung transplantation list [4, 5], for the assessment and follow-up of patients with various pulmonary diseases [6, 7] and for the evaluation of functional outcomes after pulmonary endarterectomy [8]. The walking distance (WD) during the 6MWT correlates with baseline cardiac output and peak...
oxygen uptake (VO$_2$ peak) during a maximal cardiopulmonary exercise test [9]. In patients with pulmonary arterial hypertension (PAH), advanced heart failure and idiopathic pulmonary fibrosis, the 6MWT helps to predict mortality [10–12]. However, the 6MWT yields only little information about the underlying cause of exercise limitation.

Classic symptom-limited cardiopulmonary exercise testing (CPET) is used to measure exercise capacity in patients with respiratory or cardiac diseases, to monitor treatment response and to investigate unexplained dyspnea [13, 14]. VO$_2$ peak is a strong predictor of survival in patients with primary pulmonary hypertension and an indicator for operability of pulmonary patients [15–17]. The symptom-limited CPET requires more resources than the 6MWT, but carries the advantage of providing important information in order to differentiate between a broad variety of underlying diseases.

The combination of a 6MWT with a real-time telemetric mobile cardiopulmonary monitoring (MOB) potentially adds the diagnostic power of classic CPET to the safe and time-saving procedure of the 6MWT [18]. MOB might be a superior prognostic and follow-up test compared to conventional 6MWT in patients with various potentially co-existing exercise-limiting diseases. In a previous study, we were able to demonstrate that MOB is feasible and safe in healthy individuals [18]. In this study, we evaluate the feasibility and safety of MOB in clinical routine in a larger cohort of patients with various underlying diseases and different degrees of exercise limitation. In order to exclude an impact of wearing MOB equipment on WD, conventional 6MWT and MOB were performed in randomized order on 2 consecutive days.

Patients and Methods

Study Design

The study was conducted at the University Hospital Basel, Switzerland. We included 261 consecutive patients referred to our lung function laboratory for a 6MWT between August 2003 and June 2007 to assess the feasibility, safety and diagnostic yield of MOB in clinical routine. Exclusion criteria were inability to walk, conditions preventing the use of a face mask (e.g. an anatomic face anomaly, panic disorder or claustrophobia), need for oxygen supply during walking and any acute coronary event during the previous month. The consistency of WD measured during conventional 6MWT and MOB was validated in a subset of patients in order to assess potential side effects of the MOB equipment. Twenty-one patients scheduled for a 6MWT and 12 healthy controls were recruited. 6MWT was performed with and without MOB equipment in randomized order on 2 consecutive days. Patients who had not performed a 6MWT in the previous 6 months and controls had a practice test first. Patients were excluded from the study if they had a resting $S_{p}O_2$ <85% while breathing room air. Informed consent was obtained from all participants, and the local ethics committee approved the study.

Six-Minute Walk Test

A 6MWT with pulse oxymetry was performed on an indoor walking course of 30 m according to the American Thoracic Society (ATS) guidelines [19]. At the end of the test, WD, Borg dyspnea, fatigue level and subjective reasons for exercise limitation were recorded. The 6MWT was supervised by an experienced lung function technician.

6MWT with MOB Device

The MOB device (Oxycon Mobile®; Viasys Healthcare, USA) consists of an ECG-triggered belt (Polar® Electro OY T-61) or a three-lead electrocardiograph to monitor heart rate, an oxygen sensor for the fingertip to monitor transcutaneous oxygen saturation ($S_{p}O_2$), a facemask with a dead space <30 ml and a flow sensor to measure breathing frequency and tidal volumes, a sensor unit containing the oxygen-measuring cell and the carbon dioxide analyzer, a data storage unit and a data transfer unit with integrated long-range telemetry, allowing real-time monitoring of the data on a laptop computer. The weight of the portable equipment is 950 g, including belt, battery and mask (fig. 1). In order to estimate the maximal voluntary ventilation, the first step after installation of the MOB device was to measure forced vital capacity and forced expiratory volume in the 1st s (FEV$_1$). Spirometry was followed by a resting phase until oxygen consumption (VO$_2$) and ventilation reached a steady state. The ensuing 6MWT was performed according to ATS guidelines [19] and followed by a recovery phase of 4–6 min. WD, Borg dyspnea, fatigue level and the subjective reason for limitation were recorded. MOB was supervised by an experienced lung function technician and a physician.

In order to determine the test intensity during MOB, suggestions made by the ATS for CPET were applied [20]. The effort was considered maximal if either one or more of the following criteria were fulfilled: (1) maximal heart rate ≥90% of predicted; (2) VO$_2$ peak >84% of predicted, and (3) ventilatory reserve <11 liters or <15%. VO$_2$ peak was assessed during the last 15 s of the 6MWT. Minimal $S_{p}O_2$ during MOB was recorded. VO$_2$ instabilities due to discontinuation of the 6MWT were not analyzed. Lung function parameters were interpreted according to ATS standards. Standard equations were used to calculate ventilatory reserve [1 – (VE$_{max}$/maximal voluntary ventilation)], maximal predicted values for VO$_2$ [(60 – 0.55 × age) for males and (48 – 0.37 × age) for females] and maximal predicted heart rate (220 – age) [21, 22].

Statistical Analysis

Data were analyzed using R (version 2.9.0). Results are expressed as medians (range) or means ± SD as appropriate. Comparisons between different disease categories were done using analysis of variance for parametric variables and χ² tests for differences between proportions. Spearman's rank correlation was calculated between VO$_2$ and WD. Agreement between conventional and MOB 6-min walk distance (6MWD) was tested using the Bland-Altman and linear regression analysis. Individual response patterns to exercise were analyzed using principal component analysis. Principal component analysis summarizes multivariate information into a small set of orthogonal vectors (principal com-
ponents) which extract the main sources of variation present in the dataset. Individual classification of patients into predefined diagnostic categories was assessed by between-group analysis (BGA) [23], a supervised counterpart of the principal component analysis.

**Results**

**WD of Conventional 6MWT Compared to MOB**

Thirty-three individuals (21 patients and 12 healthy controls) performed both 6MWT and MOB on consecutive days in random order (table 1). No significant difference in the WD between 6MWT and MOB was found (mean WD during 6MWT 528 ± 183 m vs. mean WD during MOB 525 ± 192 m; nonsignificant). Sixteen of the 33 participants had a longer WD during 6MWT compared to MOB, 16 performed better during MOB and 1 individual walked exactly the same distance in both tests. The test order – first 6MWT or MOB – did not significantly influence WD. Bland-Altman analysis showed good agreement between MOB and conventional WDs with a bias of 3 m (95% confidence interval: –6 to 12) and a precision of 26 m (fig. 2). Regression analysis gave a linear model with a slope of 1.04 ± 0.02 and an intercept of –25.8 ± 13.3 and shows an excellent goodness of fit (residual SE = 24.6, R² = 0.98; fig. 2).

**Feasibility and Safety of MOB**

Two-hundred forty-four patients and 17 controls performed an enhanced 6MWT with MOB. Although 131 of the 244 (54%) patients were severely impaired, with a baseline FEV₁ <50% (n = 54; 22%), a WD <300 m (n = 46; 19%) or both (n = 28; 11%), no adverse events (syncope, chest pain, arrhythmia, prolonged hypoxemia or bronchospasm) occurred. Technical problems occurred in 11 of 261 (4%) tests: evaluation of heart rate, FEV₁ and saturation were not possible in 4, 1 and 6 tests, respectively.
Although 6MWT is generally considered to be associated with submaximal effort, 155 of the 261 (59%) MOB tests reached criteria for maximal effort as specified above. Twenty-three (9%) subjects reached a heart rate above 90% of the predicted maximal heart rate, 36 (14%) subjects had VO_2_\text{peak} \geq 84\% predicted and 97 (37\%) subjects reached ventilatory limits with either ventilatory reserve <11 liters or <15\%. Twenty-four of the 155 subjects (15\%) fulfilled more than one criterion for maximal exercise.

The underlying cause of exercise limitation could be identified in 124 (48\%) tests. Eighty-six (33\%) patients had a ventilatory limitation, 27 (10\%) had a cardiocirculatory limitation and 11 (4\%) had an isolated decrease in S_pO_2 < 80\%. In half of the patients (n = 38; 51\%) with severely impaired WD < 300 m (n = 74), the underlying cause of exercise limitation could be identified. In most of the tests, limitation corresponded to the underlying disease (table 2). In several patients, the cause of exercise limitation did not correspond with the underlying disease leading to the identification of potentially treatable conditions.
co-morbidities. Some patients reached more than one criterion for maximal exercise (fig. 3). The disease-specific profiles of patients are presented in figure 4. Figure 4a displays 10 randomly chosen patients with maximal exercise test criteria from each disease group ('training set'). The first BGA axis discriminates healthy controls and cardiac disease patients from the three other groups. Cardiac patients and healthy controls had nearly identical response patterns, being in line with the fact that cardiovascular limitation is physiological. The second BGA axis discriminates between patients with pulmonary hypertension and patients with chronic obstructive pulmonary disease (COPD)/restrictive lung disease. The classification accuracy of the other patients having reached criteria for maximal exercise ('test set') was 85%. Figure 4b shows that 9 patients were misclassified, including 7 COPD patients tending to be classified as pulmonary hypertension patients. Overall, WD during MOB correlated significantly with VO₂peak in the total population (r = 0.82, p < 0.001), as well as within the different disease categories. Patients with COPD had a shorter WD for comparable VO₂ than other patients (fig. 5).

**Discussion**

The results of this study show that the use of a telemetric MOB during a conventional 6MWT is feasible in clinical routine, safe even in severely impaired patients and of higher diagnostic value than the 6MWT alone.

In our study, MOB equipment and software proved to be reliable. Minor technical problems occurred in only 4% of the tests and consisted mostly of artifacts in the readings of heart rate or SpO₂. In most cases, sufficient information for the interpretation of MOB was available. Since pulse oxymetry showed significant desaturation in most patients and even in most healthy controls, SpO₂ seemed to be of limited value. We were able to show that wearing mobile CPET equipment does not influence the 6MWD, thus enabling the comparison of WD measured by MOB and conventional 6MWT. Importantly, no serious adverse event occurred during MOB. It proved to be as safe as the conventional 6MWT even in severely impaired patients. MOB however is more time consuming than the conventional 6MWT. Overall, it took roughly 30 min for a technician to complete a test, about 10–15 min.
more than for a conventional 6MWT. Previous studies showed that telemetric measurement of metabolic and ventilatory data is feasible and safe in healthy individuals [18, 21]. Telemetric systems were used to analyze cardiorespiratory adaptations during 6MWT, and reliability and intensity of the 6MWT in patients with chronic heart failure [24, 25], COPD [26, 27] and PAH [28]. Different authors described a correlation between the 6MWD and VO2 measured during CPET on a cycle ergometer in patients with COPD [29], chronic heart failure and pulmonary hypertension [9, 10]. In these studies, the correlation coefficient between the WD and VO2 peak ranged from 0.48 for patients with PAH to 0.73 for patients with COPD. We found a correlation coefficient of 0.82 for the simultaneous measurement of WD and VO2 during 6MWT.

6MWT is generally considered to be a submaximal test [21]. However, in our study, 59% of the participants met the criteria of maximal effort. There are other reports that conclude that the 6MWT might be a maximal test in patients with heart failure [24] and COPD [30, 31]. Troosters et al. [27] compared the physiological responses to exercise during an encouraged 6MWT and an incremental cycle CPET in patients with COPD. A similar VO2 peak was found for both tests, but a VO2 plateau was typically reached after the 3rd min during the 6MWT.

Therefore, the 6MWT is believed to better assess steady-state exercise performance compared to incremental cycle CPET. A plateau of VO2 might better reflect the integrated physiologic response to exercise and, therefore, explain the high prognostic value of the 6MWT.

We observed disease-specific patterns of response to exercise. Patients with pulmonary hypertension had a particularly low VO2 peak and a low SpO2, possibly due to the pronounced impairment in diffusion leading to hypoxemia, with increased dead space ventilation due to pulmonary vascular obliteration and an insufficient rise in cardiac output during exercise due to excessively high pulmonary vascular resistance [32]. In contrast, patients with COPD had a relatively high VO2 peak at a similar WD. Probably, the reduced WD in these patients might be explained by the systemic nature of COPD with skeletal muscle involvement [33, 34] and/or a more pronounced physical deconditioning.

The present study also demonstrates that MOB compared to conventional 6MWT leads to additional diagnostic information, such as overall fitness and the cause of exercise limitation irrespective of the underlying dis-

Table 2. Demographics and exercise responses during MOB (means ± SD)

<table>
<thead>
<tr>
<th></th>
<th>Controls (n = 45)</th>
<th>Restrictive lung disease (n = 106)</th>
<th>Obstructive lung disease (n = 64)</th>
<th>PAH (n = 29)</th>
<th>Heart disease (n = 261)</th>
<th>All subjects (n = 261)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, males/females</td>
<td>9/8</td>
<td>23/22</td>
<td>61/45</td>
<td>24/40</td>
<td>17/12</td>
<td>127/134</td>
</tr>
<tr>
<td>Age, years</td>
<td>37 ± 12</td>
<td>62 ± 12</td>
<td>62 ± 14</td>
<td>61 ± 14</td>
<td>70 ± 9</td>
<td>61 ± 15</td>
</tr>
<tr>
<td>Body mass index</td>
<td>24 ± 4</td>
<td>29 ± 7</td>
<td>25 ± 6</td>
<td>27 ± 6</td>
<td>31 ± 8</td>
<td>27 ± 7</td>
</tr>
<tr>
<td>FEV1, % predicteda</td>
<td>107 ± 11</td>
<td>72 ± 22</td>
<td>49 ± 21</td>
<td>76 ± 27</td>
<td>92 ± 23</td>
<td>68 ± 29</td>
</tr>
<tr>
<td>VO2, ml/kg/min</td>
<td>32 ± 6</td>
<td>15 ± 3</td>
<td>15 ± 4</td>
<td>13 ± 3</td>
<td>14 ± 3</td>
<td>15 ± 6</td>
</tr>
<tr>
<td>VO2 peak, % predicteda</td>
<td>95 ± 16</td>
<td>66 ± 19</td>
<td>60 ± 17</td>
<td>58 ± 18</td>
<td>66 ± 14</td>
<td>63 ± 19</td>
</tr>
<tr>
<td>n &gt;84%</td>
<td>11 (65%)</td>
<td>7 (16%)</td>
<td>11 (10%)</td>
<td>5 (8%)</td>
<td>2 (7%)</td>
<td>36 (14%)</td>
</tr>
<tr>
<td>WD, m²</td>
<td>720 ± 81</td>
<td>389 ± 106</td>
<td>340 ± 123</td>
<td>339 ± 118</td>
<td>348 ± 94</td>
<td>374 ± 147</td>
</tr>
<tr>
<td>n &lt;300 m</td>
<td>0</td>
<td>7 (16%)</td>
<td>33 (31%)</td>
<td>25 (39%)</td>
<td>9 (31%)</td>
<td>74 (28%)</td>
</tr>
<tr>
<td>Ventilatory reserve, %a</td>
<td>47 ± 17</td>
<td>31 ± 19</td>
<td>21 ± 19</td>
<td>35 ± 18</td>
<td>48 ± 14</td>
<td>31 ± 21</td>
</tr>
<tr>
<td>n &lt;15% or &lt;11 liters</td>
<td>1 (6%)</td>
<td>14 (31%)</td>
<td>66 (62%)</td>
<td>15 (23%)</td>
<td>1 (3%)</td>
<td>97 (37%)</td>
</tr>
<tr>
<td>Maximal heart rate, % predictedb</td>
<td>85 ± 11</td>
<td>71 ± 12</td>
<td>69 ± 13</td>
<td>72 ± 16</td>
<td>70 ± 13</td>
<td>71 ± 14</td>
</tr>
<tr>
<td>n &gt;90%</td>
<td>6 (35%)</td>
<td>2 (4%)</td>
<td>4 (4%)</td>
<td>8 (3%)</td>
<td>3 (10%)</td>
<td>23 (9%)</td>
</tr>
<tr>
<td>Minimal SpO2, %c</td>
<td>91 ± 5</td>
<td>87 ± 7</td>
<td>87 ± 6</td>
<td>84 ± 7</td>
<td>92 ± 3</td>
<td>87 ± 7</td>
</tr>
<tr>
<td>n &lt;80%</td>
<td>0</td>
<td>8 (18%)</td>
<td>12 (11%)</td>
<td>14 (22%)</td>
<td>0</td>
<td>34 (13%)</td>
</tr>
</tbody>
</table>

a Missing values, n = 1; b missing values, n = 4; c missing values, n = 6.
ease. For example, we could identify cardiac limitation due to exercise-induced arrhythmia in patients with restrictive lung disease or ventilatory limitation in patients with pulmonary vascular disease or chronic heart disease. In these patients, MOB had a significant impact on their management. In addition, as depicted in figure 4, we could detect COPD patients with potentially underlying/associated PAH using MOB, since they showed exercise characteristics of both disease groups. Holverda et al. [35] described a large overlap in exercise test characteristics of COPD patients with and without associated pulmonary hypertension and concluded that in addition to a low ventilatory efficiency, a low resting $S_pO_2$ and accentuated decrease during exercise suggest the presence of PAH in COPD patients.

Further, the WD of a conventional 6MWT might vary due to physiologic changes, but also due to varying compliance of the patient. During MOB, the patients’ compliance and exercise quality can be assessed simultaneously by measuring heart rate, ventilatory reserves and $S_pO_2$.
during exercise. Comparing exercise intensity of consecutive tests allows a more objective assessment of changes in the response to exercise over time.

In conclusion, we could show that enhancing the 6MWT by telemetric MOB in patients with varying degree of exercise limitation is safe and clinically useful. The use of mobile CPET equipment did not negatively affect WD. WD during MOB significantly correlated with VO$_2$ peak in both maximal and submaximal tests. MOB gave additional diagnostic and disease-specific information compared to the 6MWT alone. It could identify the true cause of exercise limitation irrespective of the underlying disease and allowed to assess patients’ compliance during exercise. Therefore, in our opinion, MOB-enhanced 6MWT is a promising clinical investigative tool. Further investigations are required to investigate the role of MOB as a diagnostic and follow-up tool in specific subgroups of patients.

Acknowledgments

We are indebted to Karl Wasserman, Mitcha T. Maeder, Michael Koller and Werner Strobel for their critical review of this paper.

References


